4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Reaffirmed by Royal Bank of Canada
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at Royal Bank of Canada in a report issued on Monday, Benzinga reports. They currently have a $25.00 price objective on the stock. Royal Bank of Canada’s price objective suggests a potential upside of 40.06% from the company’s […]
More Stories
Trump Orders Navy to Replace Newer Fighter Launch System With Older Steam Catapults
By Timothy Frudd President Donald Trump ordered the Navy on Aug. 13 to return to using steam catapults to launch...
Trade Court Upholds Trump’s Shutdown of $800 De Minimis Duty Exemption
By Matthew Vadum The U.S. Court of International Trade on Aug. 13 upheld the Trump administration’s authority to end the...
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...
State Department Launches Birth Tourism Prevention Task Force
By Troy Myers The Department of State on Wednesday announced the existence of a task force that has already revoked...
Todd Blanche Sworn In as Attorney General
By Kimberly Hayek Todd Blanche, President Donald Trump’s former personal lawyer, was sworn in Monday as U.S. attorney general and...